StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) shares gain, Citi upgrades to buy as estimates ahead of consensus
April 13, 2023 10:31 AM
Merck (NYSE: MRK) was lifted to Buy from Neutral, with its price target raised to $130 from $105 by Citi ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Hot List
Upgrades
Next Articles
Delta Air Lines, Amazon, Stellantis rise premarket; Harley-Davidson falls
April 13, 2023 7:58 AM
Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
April 13, 2023 6:46 AM
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
April 13, 2023 6:45 AM
Citi Upgrades Merck (MRK) to Buy on higher estimates
April 13, 2023 2:45 AM
Merck Named One of Fortune’s 2023 100 Best Companies to Work For(R)
April 11, 2023 1:24 PM
